Fiasp

RSS

insulin aspart

Authorised
This medicine is authorised for use in the European Union.

Overview

Fiasp is a medicine that is used to treat children from one year of age and adults with diabetes. It contains the active substance insulin aspart, a rapid-acting insulin.

This EPAR was last updated on 30/10/2019

Authorisation details

Product details
Name
Fiasp
Agency product number
EMEA/H/C/004046
Active substance
insulin aspart
International non-proprietary name (INN) or common name
insulin aspart
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
A10AB05
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Novo Nordisk A/S
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
09/01/2017
Contact address
Novo Alle
2880 Bagsvaerd
Denmark

Product information

19/09/2019 Fiasp - EMEA/H/C/004046 - II/0016

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Insulins and analogues for injection
  • fast acting

Therapeutic indication

Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
3 ratings